Looks like an exciting 2013 from the J.P. Morgan Healthcare Conference

34 of 40

Clinipace President and General Counsel Chris Porter, left, and CEO Jeff Williams

There's been quite a bit of consolidation in the CRO world over the past few years, and North Carolina's Clinipace is no stranger to M&A, expanding its capabilities with four acquisitions since 2009. That's a response to the market, CEO Jeff Williams said, as small CROs are having a harder time competing and sponsors are demanding diverse abilities from their contractors. That said, Clinipace's dealmaking has put it in a position to reach out to midmarket biotechs and offer both broader options than niche CROs and far more attention than inchoate companies get from the big names in outsourcing, said Chris Porter, president and general counsel. Now that funding is a little easier to come by than in years past, it's an exciting time to be in the midmarket segment, Williams said.